echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Huahai Pharmaceutical Co., Ltd.: new specification supplement application of doxycycline hydrochloride sustained release tablets has obtained FDA temporary approval number

    Huahai Pharmaceutical Co., Ltd.: new specification supplement application of doxycycline hydrochloride sustained release tablets has obtained FDA temporary approval number

    • Last Update: 2019-06-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On June 19, Huahai pharmaceutical announced that the company's supplementary application for the new specifications of doxycycline hydrochloride sustained-release tablets declared to the US FDA was temporarily approved by the US FDA, marking that the product has passed all the review requirements of generic drugs, but the products of this specification need to be sold in the US market after the patent expires and the final approval of the FDA

    It is reported that pulinstone Pharmaceutical Co., Ltd

    is a holding subsidiary of Huahai (USA) International Co., Ltd., a wholly-owned subsidiary of Zhejiang Huahai Pharmaceutical Co., Ltd

    The brief application for new drug of doxycycline hydrochloride sustained-release tablets (specification: 50mg, 150mg, 200mg) declared by the company to the US FDA has been officially approved; the supplementary application for doxycycline hydrochloride sustained-release tablets has added 120mg specification

    Doxycycline hydrochloride sustained-release tablet is a broad-spectrum antibiotic of tetracycline

    The original drug of doxycycline hydrochloride sustained-release tablets was developed by Mayne pharma company, and was approved to be listed in the United States as early as 2008

    At present, in the United States, doxycycline hydrochloride sustained-release tablets 120mg dosage form is subject to patent protection, and the manufacturer of this specification product is only the original research Mayne pharma

    Doxycycline hydrochloride takes doxycycline as the common name in China

    The approved dosage forms include tablets, capsules, injections and other dosage forms

    The manufacturers mainly include Jiangsu Lianhuan Pharmaceutical Co., Ltd

    and Haikou Qili Pharmaceutical Co., Ltd

    and so on

    At present, no sustained-release tablet dosage forms have been approved for sale in China

    According to the query, the sales volume of doxycycline hydrochloride sustained-release tablets 120mg dosage form products in the U.S

    market in 2018 is about 12.6179 million US dollars (data from IMS database); the sales volume of doxycycline (doxycycline) preparation products (including all approved dosage form products) in domestic hospitals in 2018 is about 87.84 million yuan (data from Xianda database)

    Up to now, the company has invested 6.95 million yuan in the research and development of doxycycline hydrochloride sustained-release tablets 120mg

    This supplementary application for new specification (120mg) of doxycycline hydrochloride sustained-release tablets has obtained the FDA temporary approval number, which indicates that the product has passed all the review requirements of generic drugs, but the product of this specification needs to be qualified for sale in the U.S

    market only after the patent expires and the final approval of FDA.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.